PIRS vs. HUGE, RDHL, EDSA, PPBT, KPRX, ERNA, IMNN, TNXP, NRSN, and AKTX
Should you be buying Pieris Pharmaceuticals stock or one of its competitors? The main competitors of Pieris Pharmaceuticals include FSD Pharma (HUGE), RedHill Biopharma (RDHL), Edesa Biotech (EDSA), Purple Biotech (PPBT), Kiora Pharmaceuticals (KPRX), Eterna Therapeutics (ERNA), Imunon (IMNN), Tonix Pharmaceuticals (TNXP), NeuroSense Therapeutics (NRSN), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical preparations" industry.
Pieris Pharmaceuticals (NASDAQ:PIRS) and FSD Pharma (NASDAQ:HUGE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings, community ranking and institutional ownership.
Pieris Pharmaceuticals has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, FSD Pharma has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.
FSD Pharma has a net margin of 0.00% compared to Pieris Pharmaceuticals' net margin of -39.71%. Pieris Pharmaceuticals' return on equity of -52.88% beat FSD Pharma's return on equity.
In the previous week, Pieris Pharmaceuticals had 1 more articles in the media than FSD Pharma. MarketBeat recorded 4 mentions for Pieris Pharmaceuticals and 3 mentions for FSD Pharma. FSD Pharma's average media sentiment score of 0.68 beat Pieris Pharmaceuticals' score of -0.24 indicating that FSD Pharma is being referred to more favorably in the news media.
FSD Pharma has lower revenue, but higher earnings than Pieris Pharmaceuticals. FSD Pharma is trading at a lower price-to-earnings ratio than Pieris Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Pieris Pharmaceuticals received 278 more outperform votes than FSD Pharma when rated by MarketBeat users. Likewise, 61.50% of users gave Pieris Pharmaceuticals an outperform vote while only 0.00% of users gave FSD Pharma an outperform vote.
40.1% of Pieris Pharmaceuticals shares are held by institutional investors. Comparatively, 1.2% of FSD Pharma shares are held by institutional investors. 8.9% of Pieris Pharmaceuticals shares are held by insiders. Comparatively, 8.5% of FSD Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Pieris Pharmaceuticals beats FSD Pharma on 9 of the 14 factors compared between the two stocks.
Get Pieris Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PIRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pieris Pharmaceuticals Competitors List
Related Companies and Tools
